Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 13/20 | 0.38 |
| ▸ | KDR | P35968 | 7/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 6/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 6/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | RIPK3 | Q9Y572 | 2/20 | 0.35 |
| ▸ | FASN | P49327 | 1/20 | 0.34 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25786944 | 1.00 | RIPK2 (0.38) | RIPK2KDRTGFBR1EGFRLCK | |
| SCHEMBL31017216 | 1.00 | RIPK2 (0.38) | RIPK2KDRTGFBR1EGFRLCK | |
| SCHEMBL30886326 | 0.79 | KMT2A (0.42) | — | |
| SCHEMBL30886424 | 0.78 | KDM4E (0.37) | — | |
| SCHEMBL31254525 | 0.77 | RIPK2 (0.36) | RIPK2KDRTGFBR1EGFRLCK | |
| SCHEMBL29324929 | 0.76 | APP (0.33) | PDE10A | |
| SCHEMBL30886277 | 0.76 | ALDH1A1 (0.43) | — | |
| SCHEMBL29081200 | 0.75 | HDAC6 (0.40) | — | |
| SCHEMBL30886382 | 0.75 | TDO2 (0.36) | RIPK2KDRTGFBR1EGFR | |
| SCHEMBL30470147 | 0.74 | ALOX5AP (0.37) | RIPK2KDRTGFBR1LCKFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192679-A1 | CRYSTALLINE FORMS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | TANGO THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192679-A1 | CRYSTALLINE FORMS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | TANGO THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| WO-2023114507-A1 | CRYSTALLINE FORM OF N-(6-AMINO-5-METHYLPYRIDIN-3-YL)-2-(BENZO[D]THIAZOL-5-YL)-5-METHYLPIPERIDIN-1-YL)-2-OXOACETAMIDE, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | TANGO THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | RIPK2 4321/4885KDR 2938/4885TGFBR1 3023/4885 |
| US-20230192679-A1 | CRYSTALLINE FORMS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | PRMT5, PRMT1, PRMT3 | RIPK2 570/4885KDR 3357/4885TGFBR1 1211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.